Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-HCCS Polyclonal Antibody

Catalog #:   PHF00101 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: P53701
Overview

Catalog No.

PHF00101

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human HCCS (Met1-Ser268).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

CCHL,HCCS,Holocytochrome c-type synthase,Cytochrome c-type heme lyase

Purification

Purified by antigen affinity column.

Accession

P53701

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • WESTERN BLOT
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with HCCS antibody (PHF00101) at 1 μg/ml.

    Lane 1: Recombinant protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 33 kDa
    Observed MW: 33 kDa
References

Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers., PMID:40442146

Immunoscore Predicted by Dynamic Contrast-Enhanced Computed Tomography Can Be a Non-Invasive Biomarker for Immunotherapy Susceptibility of Hepatocellular Carcinoma., PMID:40149284

Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database., PMID:39936542

ADARp110 promotes hepatocellular carcinoma progression via stabilization of CD24 mRNA., PMID:39808660

Comparison between two artificial intelligence models to discriminate cancerous cell nuclei based on confocal fluorescence imaging in hepatocellular carcinoma., PMID:39674779

NOTCH1 drives tumor plasticity and metastasis in hepatocellular carcinoma., PMID:39484457

Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma., PMID:39417698

Causal relationship between immune cells and hepatocellular carcinoma: a Mendelian randomisation study., PMID:38947379

Anti-BIRC5 autoantibody serves as a valuable biomarker for diagnosing AFP-negative hepatocellular carcinoma., PMID:38832035

CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils., PMID:38737384

Downstaging and laparoscopic hepatectomy plus intraoperative radiofrequency ablation for the treatment of initially unresectable multifocal hepatocellular carcinomas., PMID:38283063

Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation., PMID:38222009

Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma., PMID:38214792

Phospholipase A2 Group IIA Is Associated with Inflammatory Hepatocellular Adenoma., PMID:38201587

Near-infrared photoimmunotherapy in the models of hepatocellular carcinomas using cetuximab-IR700., PMID:37817415

Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma., PMID:37625323

LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress., PMID:37540188

Overlap syndrome of autoimmune hepatitis and primary biliary cholangitis complicated with atypical hepatocellular carcinoma: a case report., PMID:37488645

Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma., PMID:37385725

Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies., PMID:37374319

Multi-dimensional single-cell characterization revealed suppressive immune microenvironment in AFP-positive hepatocellular carcinoma., PMID:37336873

A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumab-bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimen., PMID:36624210

Prediction of therapeutic response of advanced hepatocellular carcinoma to combined targeted immunotherapy by MRI., PMID:36270416

Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling., PMID:35988690

Expression of HnRNP A1, ZEB1, and E-cadherin in Hepatocellular carcinoma and their impact on patients' prognosis and survival., PMID:35900486

Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials., PMID:35785525

Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab., PMID:35700674

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma., PMID:35567547

Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma., PMID:35231914

GPC3-targeted immunoPET imaging of hepatocellular carcinomas., PMID:35147737

Stanniocalcin 1 is a serum biomarker and potential therapeutic target for HBV-associated liver fibrosis., PMID:35122667

Therapeutic efficacy of FASN inhibition in preclinical models of HCC., PMID:35076948

Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity., PMID:34796337

HCC and Molecular Targeting Therapies: Back to the Future., PMID:34680462

Significance of cytoplasmic expression of telomerase reverse transcriptase in patients with hepatocellular carcinoma undergoing liver resection., PMID:34650811

Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody., PMID:34414125

Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements., PMID:34239263

The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients' Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers., PMID:34208132

Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: a pathological, clinical and outcome study., PMID:34036629

Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma., PMID:33794926

Distinct stratification of normal liver, hepatocellular carcinoma (HCC), and anticancer nanomedicine-treated- tumor tissues by Raman fingerprinting for HCC therapeutic monitoring., PMID:33418135

Refractoriness to drugs in migraine may be the result of developing anti-drug antibodies., PMID:33360448

First evaluation of Neighbor of Punc E11 (NOPE) as a novel marker in human hepatocellular carcinoma., PMID:32986656

Antithrombin attenuates the progression of hepatocellular carcinoma by regulating neutrophil/interleukin-8 signaling., PMID:32893935

De novo hepatocellular carcinoma in living donor liver grafts: A Japanese multicenter experience., PMID:32860719

Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma., PMID:32623639

Ki-67 "hot spot" digital analysis is useful in the distinction of hepatic adenomas and well-differentiated hepatocellular carcinomas., PMID:32583014

Comparison of hepatic epithelioid angiomyolipoma and non-hepatitis B, non-hepatitis C hepatocellular carcinoma on contrast-enhanced ultrasound., PMID:32331793

Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice., PMID:32275969

The IKKβ-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis., PMID:32221968

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-HCCS Polyclonal Antibody [PHF00101]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only